These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 34725243)

  • 1. Prognostic significance of pretreatment thrombocytosis in endometrial cancer: an Israeli Gynecologic Oncology Group study.
    Tal O; Eitan R; Gemer O; Helpman L; Vaknin Z; Leytes S; Lavie O; Ben-Arie A; Amit A; Namazov A; Ben Shahar I; Atlas I; Bruchim I; Levy T
    Int J Gynecol Cancer; 2021 Nov; 31(11):1437-1442. PubMed ID: 34725243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Significance of Pretreatment Thrombocytosis and Its Association With Neutrophilia in Patients With Surgically Treated Endometrial Cancer.
    Takahashi R; Mabuchi S; Kuroda H; Kozasa K; Yokoi E; Matsumoto Y; Kimura T
    Int J Gynecol Cancer; 2017 Sep; 27(7):1399-1407. PubMed ID: 28604454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative thrombocytosis as a prognostic factor in endometrioid-type endometrial carcinoma.
    Abu-Zaid A; Alsabban M; Abuzaid M; AlOmar O; Salem H; Al-Badawi IA
    Ann Saudi Med; 2017; 37(5):393-400. PubMed ID: 28988254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.
    Prueksaritanond N; Chantape W
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative thrombocytosis and poor prognostic factors in endometrial cancer.
    Heng S; Benjapibal M
    Asian Pac J Cancer Prev; 2014; 15(23):10231-6. PubMed ID: 25556452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
    Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodal metastasis in endometrial cancer.
    Willis G; Misas JE; Byrne W; Podczaski E
    Eur J Gynaecol Oncol; 2011; 32(3):259-63. PubMed ID: 21797112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
    Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
    J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
    Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
    Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
    McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
    Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the lymphadenectomy in high-risk histologic types of endometrial cancer: a matched-pair study.
    Coronado PJ; Fasero M; Baquedano L; Martinez-Maestre MA; Casado A; Vidart JA; Herraiz MA
    Int J Gynecol Cancer; 2014 May; 24(4):703-12. PubMed ID: 24651627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Circulating Lymphocyte and Monocyte Counts Correlate with Patient Outcomes in Type I and Type II Endometrial Cancer.
    Burgess B; Levine B; Taylor RN; Kelly MG
    Reprod Sci; 2020 Jan; 27(1):194-203. PubMed ID: 32046381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population.
    Gorelick C; Andikyan V; Mack M; Lee YC; Abulafia O
    Int J Gynecol Cancer; 2009 Nov; 19(8):1384-9. PubMed ID: 20009894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of lymphovascular space invasion and nodal involvement in intermediate- and high-risk endometrial cancer patients treated with curative intent using surgery and adjuvant radiotherapy.
    Narayan K; Khaw P; Bernshaw D; Mileshkin L; Kondalsamy-Chennakesavan S
    Int J Gynecol Cancer; 2012 Feb; 22(2):260-6. PubMed ID: 22080878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment hemoglobin, platelet count, and prognosis in endometrial carcinoma.
    Tamussino KF; Gücer F; Reich O; Moser F; Petru E; Scholz HS
    Int J Gynecol Cancer; 2001; 11(3):236-40. PubMed ID: 11437932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
    Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
    Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival.
    Bristow RE; Zahurak ML; Alexander CJ; Zellars RC; Montz FJ
    Int J Gynecol Cancer; 2003; 13(5):664-72. PubMed ID: 14675352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a survival advantage in diagnosing endometrial cancer in asymptomatic postmenopausal patients? An Israeli Gynecology Oncology Group study.
    Gemer O; Segev Y; Helpman L; Hag-Yahia N; Eitan R; Raban O; Vaknin Z; Leytes S; Ben Arie A; Amit A; Levy T; Namazov A; Volodarsky M; Ben Shachar I; Atlas I; Bruchim I; Lavie O
    Am J Obstet Gynecol; 2018 Aug; 219(2):181.e1-181.e6. PubMed ID: 29792852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.